An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A new clinical guidance document suggests that certain drugs called incretin-based therapies can be used as an add-on treatment for some people with type 1 diabetes. The guidance doesn’t say everyone with type 1 should take these drugs. Instead, it offers doctors advice on when and how to consider them alongside insulin, based on recent studies and expert opinion. An incretin is a natural hormone made in the gut after you eat that helps control blood sugar. Drugs that act on incretins include GLP-1 receptor agonists (you may have heard of semaglutide, the active ingredient in Ozempic and Wegovy). These medicines mimic the gut hormone’s effects: they help the body release less glucose into the blood, slow how fast the stomach empties, and reduce appetite. They are primarily approved for type 2 diabetes and weight loss, not for type 1 diabetes, which is an autoimmune condition where the body largely stops making insulin. The guidance summarizes research where incretin drugs were given in addition to insulin to people with type 1 diabetes. The studies have been small and mixed. In some trials, patients saw modest improvements in blood sugar control and weight loss; in others, benefits were limited or came with more low blood-sugar events (hypoglycemia) or diabetic ketoacidosis (a rare but serious complication). Most of the evidence comes from short-term studies or small groups rather than large, long-term trials, so the picture is still incomplete. Why this matters is practical. If someone with type 1 diabetes is struggling with excess weight, high blood sugars despite insulin, or large swings in glucose, a doctor might consider adding an incretin drug as an off-label option when guided by these recommendations. The guidance gives clinicians a framework to weigh potential benefits against risks and to monitor patients closely if they try these drugs. This could expand options for some patients, but it is not a broad endorsement for routine use. There are important caveats. Incretin drugs are not approved for type 1 diabetes in most places, so using them is often off-label. They can increase the risk of hypoglycemia if insulin doses aren’t adjusted, and there have been signals for diabetic ketoacidosis in some studies. Common side effects include nausea and gastrointestinal upset. Long-term safety and benefit specifically in type 1 diabetes are not established, and these drugs may not be appropriate for people with certain medical histories. Anyone interested should discuss risks and monitoring plans with their diabetes team rather than starting medication on their own. Bottom line: experts have produced guidance for cautious, selective use of incretin drugs as an add-on to insulin in type 1 diabetes, but the evidence is limited and careful medical supervision is essential.
Source: Medscape